PNC-27 Peptide

Description

PNC-27 Peptide

PNC-27 Peptide is a synthetic anticancer peptide designed for targeted cancer therapy. It is derived from the HDM-2 binding domain of the tumor suppressor protein p53, a protein critical for controlling cell cycle and apoptosis. Preclinical studies indicate that PNC-27 selectively induces apoptosis in tumor cells while leaving normal healthy cells largely unaffected.

The peptide’s design allows it to recognize malignant cells that overexpress HDM-2 proteins, a common feature in many cancer types. This selective mechanism forms the basis for its tumor-targeted activity in experimental models.

Handling and Storage of PNC-27 Peptide

The peptide compound should be stored in a cool and dry place to maximize its stability. For PNC-27 Peptide lyophilized peptides, it is recommended to store them in the refrigerator between 2°C and 8°C (36°F–46°F) in an airtight container. 

Lab user exposure: 

• Avoid prolonged or repeated exposure.
• Avoid inhalation.
• Avoid contact with eyes or skin.
• Handle inside standard laboratory containment.
• Use gloves, a lab coat, and protective eyewear.

Redissolving:

• Can be reconstituted in sterile distilled water or suitable buffer solutions.qvff
• A small amount of DMSO or 0.1% TFA may be used to test or improve solubility.
• Mix gently, avoid high-temperature heating. 

Choice of container and precautions:

• Low-binding sterile polypropylene to prevent adsorption
• Borosilicate glass vials to prevent adsorption in the glass walls
• Avoid polystyrene
• Avoid lab plastic containers 

Working Mechanism of PNC-27 Peptide

Research-based studies and laboratory models suggest that PNC-27 Peptide functions via multiple biological pathways:

• PNC-27 binds specifically to HDM-2 proteins expressed on the surface of tumor cells.This selective binding differentiates malignant cells from normal healthy cells, allowing precise targeting of tumors in preclinical models.

• Upon binding to HDM-2, PNC-27 integrates into the cancer cell membrane.It forms transmembrane pore complexes, disrupting cellular membrane integrity. This leads to programmed cell death (apoptosis) without triggering necrosis, ,

• which minimizes inflammation in surrounding tissues.

• PNC-27 interferes with the HDM-2/p53 interaction, preventing p53 degradation in cancer cells. The freed p53 protein activates transcription of apoptotic genes, further promoting cancer cell death. This dual mechanism (membrane pore formation + p53 activation) enhances the peptide’s antitumor efficacy.

• Laboratory models show minimal cytotoxicity in non-cancerous cells, emphasizing the peptide’s tumor-selective action.
  

Potential Benefits of PNC-27 Peptide

Based on preclinical evidence, PNC-27 Peptide may:

• Selectively induce apoptosis in cancer cells without affecting normal tissues.
  
• Reduce tumor growth and proliferation in experimental cancer models.
  
• Activate tumor suppressor p53, restoring critical apoptotic pathways.
• Minimize off-target toxicity compared to traditional chemotherapy.
  
• Serve as a platform for developing targeted peptide-based cancer therapies.
  

Potential Side Effects (Observed in Laboratory Models)

In experimental studies, the following effects have been reported:

• Mild cytotoxicity at high concentrations in some cell types.
  
• Minimal impact on healthy non-malignant cells.
  
• No significant inflammatory response due to apoptosis-based mechanisms.

Disclaimer

PNC-27 Peptide is intended exclusively for laboratory research purposes. RCDbio products are not intended to diagnose, treat, cure, or prevent any disease. The Food and Drug Administration has not evaluated the statements on our website. By purchasing, you agree to our Terms and Conditions.